Biotechnology Industry
Filter News
Found 11,370 articles
-
BioSpace Movers and Shakers: Jan. 18
1/18/2019
Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more. -
Bayer introduces versatile new option for heartworm prevention and intestinal parasite control
1/18/2019
Bayer Animal Health announces the launch of Coraxis™ (moxidectin) Topical Solution for Dogs, a prescription-only, monthly transdermal product that prevents heartworm disease and treats and controls hookworms, roundworms, and whipworms in dogs.
-
Can-Fite BioPharma Announces Registered Direct Offering
1/18/2019
Can-Fite BioPharma Ltd. today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million.
-
Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer
1/18/2019
Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning
-
Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner
1/18/2019
Moderna, Inc. today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner. He will be a strategic consultant to Moderna for six months to ensure a smooth transition.
-
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
1/18/2019
- Celgene gains exclusive options to two Kyn therapeutic programs
-
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings
1/18/2019
Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity
-
SQZ Biotech is on a roll. Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, the company is now expanding its footprint in Watertown, Mass.
-
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
-
The researchers identified a group of centyrins that blocked the action of five toxins generated by Staphylococcus aureus, the bacteria that causes Staph infections.
-
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
1/17/2019
MANF Therapeutics announced it has received a notice of allowance from the European Patent Office covering the use of MANF as a treatment for various neurodegenerative disorders, including Parkinson’s disease, as well as a notice of allowance from the Japanese Patent Office covering the use of MANF as a treatment for diabetes and other beta-cell disorders.
-
Cees de Jong: new Chairman of the joint start-up A-Mansia Biotech
1/17/2019
A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors.
-
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
1/17/2019
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
-
Medigene AG: Medigene participates at four upcoming conferences
1/17/2019
Medigene AG announced its participation at the following upcoming investor and scientific conferences
-
Smile Direct Club Announces New Senior Leadership Appointments and Promotions to Support Its Rapid International Growth
1/17/2019
SmileDirectClub, the market leader and pioneer of doctor-directed, remote invisible aligner therapy, today announced new appointments and promotions on its executive team consistent with its mission of bringing everyone access to a confident smile.
-
Ottawa dentist sentenced for tax fraud and laundering proceeds of crime
1/17/2019
The Canada Revenue Agency (CRA) announced that, on January 17, 2019, Kin Tung Fong (Fong) of Ottawa, Ontario, was sentenced in the Ontario Court of Justice in Ottawa to a conditional jail sentence of two years less a day, including 12 months of house arrest, and curfew for the remainder of the sentence.
-
PharmaCyte Biotech’s CEO Interviewing Live on The Big Biz Show
1/17/2019
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its Chief Executive Officer, Kenneth L. Waggoner, will be featured in a live interview on “The Big Biz Show,” an Emmy Award-winning nationally syndicated radio and TV program, on Friday, January 18th.
-
Revance Announces Pricing of Public Offering of 5,882,353 Shares of Its Common Stock
1/17/2019
Revance Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share.
-
LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019
1/17/2019
LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced today that it will be presenting its novel whole genome sequencing (WGS) interpretation solutions at Precision Medicine World Conference 2019 in Silicon Valley, on January 22nd, as part of the Clinical and Research Tools Showcase.
-
Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
1/17/2019
Aerpio Pharmaceuticals, Inc. today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).